Login to Your Account



In The Clinic NEWS

About the 5 percent drop in overall response rate in the expanded phase I trial with the company’s ADC for ovarian cancer, Immunogen Inc.’s chief development officer, Charles Morris, said he was “not sure I’d call it significant.”

Positive data with Oncosec Medical Inc.'s Immunopulse interleukin-12 electroporation therapy against melanoma "set pulses racing," in the words of H.C. Wainwright analyst Mark Breidenbach.

NEW ORLEANS – From a therapeutic point of view, having a bigger genomic mess is in some ways easier to deal with than a smaller one.

More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: